BioSpace News Archive

Akari Therapeutics, Plc announced financial results for the quarter ended March 31, 2022, as well as research and development progress on nomacopan and long-acting PAS-nomacopan.

CAMP4 Therapeutics, a biotechnology company harnessing the power of RNA to restore healthy protein expression, announced the closing of a $100 million Series B round to advance the company’s lead regRNA programs and accelerate the expansion of the company’s regRNA Actuating Platform.

Biodesix, Inc. announced that Young Kwang Chae, MD, MPH, MBA, Associate Professor of Medicine Feinberg School of Medicine, Northwestern University will present the results of a retrospective analysis at the IASLC 2022 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer on August 8, 2022 in Vienna, Austria.

Nanomerics Ltd., a private speciality pharmaceutical company, announced that the company’s Chief Scientific Officer, Professor Ijeoma F. Uchegbu, had been made an Honorary Fellowship of the UK’s Royal Society of Chemistry.

Caris Life Sciences®, the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced that Northside Hospital Cancer Institute has joined Caris’ Precision Oncology Alliance™.

Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, announced two leadership team promotions.

Siolta Therapeutics announced that the first newborn subject has been dosed in the adored study, a Phase 1b/2 trial of STMC-103H, a potential first-in-class microbiome-based therapeutic for the prevention of atopic diseases.

Merck, known as MSD outside the United States and Canada, announced that the Phase 3 KEYNOTE-412 trial evaluating KEYTRUDA®, Merck’s anti-PD-1 therapy, with concurrent chemoradiation therapy followed by KEYTRUDA as maintenance therapy, did not meet its primary endpoint of event-free survival for the treatment of patients with unresected locally advanced head and neck squamous cell carcinoma.

George Medicines today announces it has advanced GMRx4, its novel proprietary ultra-low-dose triple combination candidate as a first-line treatment for type 2 diabetes into Phase II clinical development.

TELA Bio, Inc. today announced that it has been awarded a group purchasing agreement for Synthetic Bioabsorbable Mesh Products with Premier, Inc.